Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study

Atherosclerosis

Volumn 165, Issue 1, 2002, Pages 153-158

  Zito, Francesco ^a   Lowe, Gordon D O ^b   Rumley, Ann ^b   McMahon, Alex D ^c   Humphries, Steve E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Coronary heart disease; Factor XII; Genotype

Indexed keywords

BLOOD CLOTTING FACTOR 12; CHOLESTEROL; FIBRINOGEN; LIPID; PLACEBO; PRAVASTATIN;

ADULT; AGE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; DNA POLYMORPHISM; FIBRINOLYSIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ANTILIPEMIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY DISEASE; FACTOR XII; GENETIC MARKERS; GENOTYPE; GREAT BRITAIN; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROBABILITY; RISK ASSESSMENT; RISK FACTORS;

EID: 0036840704     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00196-X     Document Type: Article

References (37)

1. Saito H. The contact phase of blood coagulation. Bloom A.L., Forbes C.D., Thomas D.P., Tuddenham E.G.D., Haemost and thrombosis. 3rd ed. 1994;289-307 Churchill Livingstone, London.
2. Hojima Y., Cochrane C.G., Wiggins R.C., Austen K.F., Stevens R.L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate. Blood. 63:1984;1453-1459.
3. Kaplan A.P., Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 70:1987;1-15.
4. Bouma B.N., Griffin J.H. Human blood coagulation factor XI: purification, properties, and mechanism of activation by activated factor XII. J. Biol. Chem. 252:1977;6432-6437.
5. Mandle R., Kaplan A.P. Hageman factor substrates: human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J. Biol. Chem. 252:1977;6097-6104.
6. Kerbiriou D.M., Griffin J.H. Human high molecular weight kininogen: studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J. Biol. Chem. 254:1979;12020-12027.
7. Ghebrehiwet B., Randazzo B.P., Duan H.T., Silverberg M., Kaplan A.P. Mechanism of activation of the classical pathway of complement by Hageman factor fragment. J. Clin. Invest. 71:1983;1450-1456.
8. Ratnoff O.D., Davie E.W. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI). Biochemistry. 1:1962;677-685.
9. Seligsohn U., Osterud G., Brown S.F., Griffin J.H., Rapaport S.I. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein and activated factor XII. J. Clin. Invest. 64:1979;1056-1065.
10. Miles L.A., Greengard J.S., Griffin J.H. A comparison of the abilities of plasma kallikrein, β-factor XIIa, factor XIa, and urokinase to activate plasminogen. Thromb. Res. 29:1983;407-417.
11. Lenich C., Pannell R., Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb. Haemost. 74:1995;698-703.
12. Braat E.A., Dooijevard G., Rijken D.C. Fibrinolytic properties of activated FXII. Eur. J. Biochem. 263:1999;904-911.
13. Schousboe I., Feddersen K., Rojkjaer R. Factor XIIa is a kinetically favorable plasminogen activator. Thromb. Haemost. 82:(3):1999;1041-1046.
14. Gordon E.M., Hellerstein H.K., Ratnoff O.D., Arafah B.M., Yamashita T.S. Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII and spontaneous shortening of prothrombin time in survivors of myocardial infarction. J. Lab. Clin. Med. 109:1987;409-413.
15. Kohler H.P., Carter A.M., Stickland M.H., Grant P.J. Levels of activated FXII in survivors of mycardial infarction - association with circulating risk factors and extent of coronary artery disease. Thromb. Haemost. 79:1998;14-18.
16. Kohler H.P., Futers T.S., Grant P.J. FXII (46C→T) polymorphism and in vivo generation of FXII activity. Thromb. Haemost. 81:1999;745-747.
17. Kelleher C.C., Mitropoulos K.A., Imeson J., Meade T.W., Martin J.C., Reeves B.E.A., Hughes L.O. Hageman factor and risk of myocardial infarction in middle-aged men. Atherosclerosis. 92:1992;67-73.
18. Miller G.J., Esnouf M.P., Burgess A.I., Cooper J.A., Mitchell J.P. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler. Thromb. Vasc. Biol. 17:1997;2103-2106.
19. Zito F., Drummond F., Bujac S.R., Esnouf M.P., Morrissey J.H., Humphries S.E., Miller G.J. Epidemiologic and genetic associations of activated factor XII concentration with factor VII activity, fibrin generation, and risk of coronary heart disease in men. Circulation. 102:2000;2058-2062.
20. Kanaji T., Okamura T., Osaki K., Kuroiwa M., Shimoda K., Hamasaki N., Noho Y. A common genetic polymorphism (46C to T Substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood. 6:1998;2010-2014.
21. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men hypercholesterolemia. West of Scotland Coronary Prevention Study. New Engl. J. Med. 333:1995;1301-1307.
22. Dick J., McClaren M., Ford R. The effect of atorvastatin on activated factor XII, fibrinogen and lipid profile. Haemostasis. 30:2000;30-97.
23. The WOSCOPS group . Baseline risk factors and their associations with outcome in the West of Scotland Coronary Prevention Study. Am. J. Cardiol. 79:1997;756-762.
24. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis. Manual of Laboratory Operations vol. I, Department of Health, Education and Welfare 1974; Publication No.75-628. National Institute of Health, Bethesda, MD.
25. Ford R.P., Esnouf M.P., Burgess A.I., Sarphie A.F. An enzyme linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. J. Immunoassay. 17:1996;119-131.
26. Lowe G.D.O., Yarnell J.W., Sweetnam P.M., Rumley A., Thomas H.F., Elwood P.C. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb. Haemost. 79:1998;129-133.
27. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1988;1215.
28. Day I.N.M., Humphries S. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal. Biochem. 222:1994;389-395.
29. Kozak M. The scanning model for translation: an update. J. Cell Biol. 108:1989;229-241.
30. Pedersen O.D., Munkvad S., Gram J., Kluft C., Jespersen J. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur. Heart J. 14:1993;785-789.
31. Munkvad S., Jespersen J., Gram J., Kluft C. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J. Am. Coll. Cardiol. 17:1991;957-962.
32. Lowe G.D.O., Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombosis. Thromb. Haemost. 82:1999;667-672.
33. Cushman M., Lemaitre R.N., Kuller L.H., Psaty B.M., Macy E.M., Sharrett A.R., Tracy R.P. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 19:1999;493-498.
34. Jansen P.M., Pixley R.A., Brouwer M., et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin 6 and neutrophil elastase. Blood. 87:1996;2337-2344.
35. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32:1998;2057-2064.
36. Schloesser M., Zeerleder S., Lutze G., et al. Mutations in the human Factor XII gene. Blood. 90:1997;3967-3977.
37. Hoffmeister H.M., Jur M., Wendel H.P., Heller W., Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in acute and post acute phases in patients with unstable angina pectoris. Circulation. 91:1985;2520-2527.